ANI Pharmaceuticals received FDA approval for the Abbreviated New Drug Application – ANDA – and launched Naproxen Delayed-Release Tablets, USP. ANI’s Naproxen Delayed-Release Tablets is the generic version of the reference listed drug EC-Naprosyn. U.S. annual sales for Naproxen Delayed-Release Tablets total approximately $36.7M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $94 from $87 at H.C. Wainwright
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner
- ANI Pharmaceuticals Announces Merger and Secures Financing
- ANI Pharmaceuticals sees ‘substantial accretion’ from Alimera Sciences deal
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences